MedTech Dive December 4, 2023
The company expects the acquisition to be revenue accretive starting in 2024.
Dive Brief:
- Nevro acquired Vyrsa Technologies, a company that makes a minimally invasive treatment for chronic sacroiliac joint pain, the companies announced on Thursday.
- Nevro agreed to pay $40 million upfront and an additional $35 million in milestone payments. It values the SI joint market at more than $2 billion and expects it to grow by double digits over the next several years.
- The purchase could help spark investor interest in Nevro, J.P. Morgan analyst Robbie Marcus wrote in a research note. “Ultimately, we think the main priority for investors will continue to be the outlook for [spinal cord stimulation] and Nevro’s ability to either hold...
Today's Sponsors
Today's Sponsor